1. Home
  2. SJT vs NBP Comparison

SJT vs NBP Comparison

Compare SJT & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SJT

San Juan Basin Royalty Trust

N/A

Current Price

$3.28

Market Cap

139.8M

Sector

Energy

ML Signal

N/A

NBP

NovaBridge Biosciences American Depositary Shares

N/A

Current Price

$1.20

Market Cap

149.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SJT
NBP
Founded
1980
2014
Country
United States
United States
Employees
495
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.8M
149.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SJT
NBP
Price
$3.28
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $9.00
AVG Volume (30 Days)
376.1K
★ 417.1K
Earning Date
11-12-2026
08-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.37
$1.19
52 Week High
$6.55
$5.19

Technical Indicators

Market Signals
Indicator
SJT
NBP
Relative Strength Index (RSI) 41.30 34.10
Support Level $2.68 N/A
Resistance Level $3.27 $1.45
Average True Range (ATR) 0.30 0.09
MACD -0.09 -0.00
Stochastic Oscillator 7.55 14.52

Price Performance

Historical Comparison
SJT
NBP

About SJT San Juan Basin Royalty Trust

San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.

About NBP NovaBridge Biosciences American Depositary Shares

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

Share on Social Networks: